Научные интересы

Научные интересы включают генетику, патофизиологию, биомаркеры, новые технологии диагностики и лечения сахарного диабета 2 типа и его осложнений (макроангиопатии, хронической болезни почек, неалкогольной жировой болезни печени), ожирения, остеопороза.

Научные публикации

Klimontov VV, Saik OV, Korbut AI. Glucose Variability: How Does It Work? Int J Mol Sci. 2021;22(15):7783. doi: 10.3390/ijms22157783.
Klimontov VV, Koroleva EA, Khapaev RS, Korbut AI, Lykov AP. Carotid Artery Disease in Subjects with Type 2 Diabetes: Risk Factors and Biomarkers. J Clin Med. 2021;11(1):72. doi: 10.3390/jcm11010072.
Saik OV, Klimontov VV. Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks. Int J Mol Sci. 2021;22(22):12419. doi: 10.3390/ijms222212419.
Klimontov VV, Korbut AI, Taskaeva IS, Bgatova NP, Dashkin MV, Orlov NB, Khotskina AS, Zavyalov EL, Klein T. Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice. World J Diabetes. 2020;11(12):596-610. doi: 10.4239/wjd.v11.i12.596.
Saik OV, Klimontov VV. Bioinformatic Reconstruction and Analysis of Gene Networks Related to Glucose Variability in Diabetes and Its Complications. Int J Mol Sci. 2020;21(22):8691. doi: 10.3390/ijms21228691.
Klimontov VV, Korbut AI, Orlov NB, Dashkin MV, Konenkov VI. Multiplex Bead Array Assay of a Panel of Circulating Cytokines and Growth Factors in Patients with Albuminuric and Non-AlbuminuricDiabetic Kidney Disease. J Clin Med. 2020;9(9):3006. doi: 10.3390/jcm9093006.
Korbut AI, Taskaeva IS, Bgatova NP, Muraleva NA, Orlov NB, Dashkin MV, Khotskina AS, Zavyalov EL, Konenkov VI, Klein T, Klimontov VV. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes. Int J Mol Sci. 2020;21(8):2987. doi: 10.3390/ijms21082987.
Korbut AI, Klimontov VV, Vinogradov IV, Romanov VV. Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes. World J Diabetes. 2019;10(11):517-533. doi: 10.4239/wjd.v10.i11.517.
Klimontov VV, Bulumbaeva DM, Fazullina ON, Lykov AP, Bgatova NP, Orlov NB, Konenkov VI, Pfeiffer AFH, Pivovarova-Ramich O, Rudovich N. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. J Cell Commun Signal. 2020;14(1):101-109. doi: 10.1007/s12079-019-00536-4.
Климонтов В.В., Мякина Н.Е. Вариабельность гликемии при сахарном диабете. Монография, 2-е изд., испр. и доп. – Новосибирск: ИПЦ НГУ, 2018. – 246 с.

Премии и награды

Персональные профили исследователя

Web of Science: R-7689-2017
Scopus: 8295977000
РИНЦ: 629434
ORCID: 0000-0002-5407-8722
MathSciNet: